title: A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
abstract: BACKGROUND
  Drug-eluting metallic coronary stents predispose to late stent thrombosis, prevent late lumen vessel enlargement, hinder surgical revascularisation, and impair imaging with multislice CT. We assessed the safety of the bioabsorbable everolimus-eluting stent (BVS).
  
  
  METHODS
  30 patients with a single de-novo coronary artery lesion were followed up for 2 years clinically and with multiple imaging methods: multislice CT, angiography, intravascular ultrasound, derived morphology parameters (virtual histology, palpography, and echogenicity), and optical coherence tomography (OCT).
  
  
  RESULTS
  Clinical data were obtained from 29 of 30 patients. At 2 years, the device was safe with no cardiac deaths, ischaemia-driven target lesion revascularisations, or stent thromboses recorded, and only one myocardial infarction (non-Q wave). 18-month multislice CT (assessed in 25 patients) showed a mean diameter stenosis of 19% (SD 9). At 2-year angiography, the in-stent late loss of 0.48 mm (SD 0.28) and the diameter stenosis of 27% (11) did not differ from the findings at 6 months. The luminal area enlargement on OCT and intravascular ultrasound between 6 months and 2 years was due to a decrease in plaque size without change in vessel size. At 2 years, 34.5% of strut locations presented no discernible features by OCT, confirming decreases in echogenicity and in radiofrequency backscattering; the remaining apparent struts were fully apposed. Additionally, vasomotion occurred at the stented site and adjacent coronary artery in response to vasoactive agents.
  
  
  CONCLUSIONS
  At 2 years after implantation the stent was bioabsorbed, had vasomotion restored and restenosis prevented, and was clinically safe, suggesting freedom from late thrombosis. Late luminal enlargement due to plaque reduction without vessel remodelling needs confirmation.
authors.affiliation: Thorax Center, Erasmus Medical Center, Rotterdam, Netherlands.
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: John A
authors.initials: JA
authors.lastname: Ormiston
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Onuma
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Nieves
authors.initials: N
authors.lastname: Gonzalo
authors.forename: Hector M
authors.initials: HM
authors.lastname: Garcia-Garcia
authors.forename: Koen
authors.initials: K
authors.lastname: Nieman
authors.forename: Nico
authors.initials: N
authors.lastname: Bruining
authors.forename: Cécile
authors.initials: C
authors.lastname: Dorange
authors.forename: Karine
authors.initials: K
authors.lastname: Miquel-Hébert
authors.forename: Susan
authors.initials: S
authors.lastname: Veldhof
authors.forename: Mark
authors.initials: M
authors.lastname: Webster
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
mesh_terms: D020341:Absorbable Implants; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology* / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D020123:Sirolimus / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus